Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480988 | 1.00 | HSD17B10 (0.47) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| SCHEMBL1685922 | 1.00 | HSD17B10 (0.47) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| Piperazine SCHEMBL28831394 | 0.97 | HSD17B10 (0.45) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| Piperazine SCHEMBL28831395 | 0.97 | HSD17B10 (0.45) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| SCHEMBL7995550 | 0.88 | PARP1 (0.44) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| SCHEMBL2584375 | 0.88 | PARP1 (0.44) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| SCHEMBL18673224 | 0.88 | PARP1 (0.44) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| SCHEMBL28704904 | 0.88 | PARP1 (0.44) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| SCHEMBL15402543 | 0.86 | PARP1 (0.43) | HSD17B10PARP1SMN1; SMN2NPC1MC4R | |
| SCHEMBL17560433 | 0.86 | PARP1 (0.43) | HSD17B10PARP1SMN1; SMN2NPC1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| EP-4637926-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250236593-A1 | SMALL MOLECULES THAT SENSITIZE HIV-1 INFECTED CELLS TO ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY | UNIV PENNSYLVANIA (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12286434-B2 | Pan-tropic entry inhibitors | EMORY UNIVERSITY (US) | 2025-04-29 | — | — | US | disclosed |
| US-12286401-B2 | Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| CN-119431317-A | Cyanuric chloride trisubstituted amine derivative as antiviral, preparation method and application thereof | 中国科学院上海药物研究所 | 2025-02-14 | — | — | CN | disclosed |
| EP-1037905-A1 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| CN-1052231-C | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2000-05-10 | — | — | CN | disclosed |
| US-5962487-A | PICORNAVIRAL 3C PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999031122-A9 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMA (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999031122-A1 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| CN-1097421-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1995-01-18 | — | — | CN | disclosed |
| WO-1995000498-A1 | N,N-DIACYLPIPERAZINES | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5348955-A | Angiotensis II antagonists | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236593-A1 | SMALL MOLECULES THAT SENSITIZE HIV-1 INFECTED CELLS TO ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY | CD4, NFATC1, GZMB | HSD17B10 4288/4885PARP1 557/4885SMN1; SMN2 3435/4885 |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | HSD17B10 1500/4885PARP1 1598/4885SMN1; SMN2 1337/4885 |
| US-12286401-B2 | Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity | CD4, NFATC1, GZMB | HSD17B10 4288/4885PARP1 557/4885SMN1; SMN2 3435/4885 |
| US-12286434-B2 | Pan-tropic entry inhibitors | CXCR4, CCR5, CXCL12 | HSD17B10 4000/4885PARP1 630/4885SMN1; SMN2 2765/4885 |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | HSD17B10 1500/4885PARP1 1598/4885SMN1; SMN2 1337/4885 |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | HSD17B10 1559/4885PARP1 1716/4885SMN1; SMN2 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.